Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Eli Lilly reported Phase 3 BRUIN CLL-322 results for Jaypirca (pirtobrutinib) plus venetoclax and rituximab versus venetoclax and rituximab alone in relapsed/refractory CLL/SLL. The addition reduced the risk of progression or death by 45% (IRC-assessed PFS: HR 0.55, p=0.0001). Median PFS was not reached vs 39.7 months. Safety showed similar Grade ≥3 AEs. Data will be presented at EHA 2026.
Positive Phase 3 readout strengthens Jaypirca’s CLL/SLL combination positioning and supports potential label expansion with regulatory submissions.
Eli Lilly reported Phase 3 BRUIN CLL-322 results where adding Jaypirca to venetoclax/rituximab cut PFS risk of progression/death by 45% (HR 0.55).
Near-term upside bias for LLY on biotech/oncology sentiment, with follow-through tied to EHA late-breaking presentation and any subsequent regulatory/label narrative.
Background
BRUIN CLL-322 is a Phase 3 trial testing whether pirtobrutinib (Jaypirca) improves outcomes when added to a time-limited venetoclax plus rituximab regimen in relapsed/refractory CLL/SLL, including patients previously treated with covalent BTK inhibitors.
Why it matters
The newest concrete fact is the statistically significant improvement in IRC-assessed progression-free survival: adding pirtobrutinib reduced the risk of progression or death by 45% (HR 0.55, p=0.0001), with median PFS not reached in the combination arm versus 39.7 months in the control arm. OS is not yet mature, but TTNT also favored the combination (HR 0.50). Lilly indicates plans to submit to global regulators to expand Jaypirca’s label.
Market relevance
A Phase 3 primary endpoint win with a large hazard ratio and consistent subgroup effects is a material catalyst for Lilly’s oncology pipeline narrative, though OS remains pending.
Market effects
Reinforces the competitive value of non-covalent BTK inhibition in CLL, potentially shifting expectations for next-line regimens beyond venetoclax/rituximab alone.
Primarily US-listed pharma/biotech sentiment; EHA timing can drive European conference-driven positioning.
Global CLL treatment paradigm implications may affect international payer/clinical guideline discussions if results translate into practice.
Alternative perspectives
Overall survival is not yet mature (OS HR 0.89, not significant/undetermined), so the market may eventually discount PFS-only gains if OS benefit is not confirmed.
Safety is broadly consistent but includes higher Grade ≥3 neutropenia and a lower tumor lysis syndrome rate; traders may watch for any emerging tolerability signals at longer follow-up and in OS analyses.
Key entities
- companyEli Lilly and Company
Sponsor of BRUIN CLL-322; reported Phase 3 primary endpoint success for Jaypirca plus venetoclax/rituximab in relapsed/refractory CLL/SLL.
- drugJaypirca (pirtobrutinib)
Non-covalent BTK inhibitor tested as an add-on to a time-limited venetoclax/rituximab regimen.
- clinical_trialBRUIN CLL-322
Global randomized Phase 3 study comparing pirtobrutinib+venetoclax+rituximab vs venetoclax+rituximab in previously treated CLL/SLL.
- eventEuropean Hematology Association (EHA) Annual Meeting 2026
Late-breaking oral presentation venue for the trial results.
